420 with CNW — Novel Study Highlights Effects of High-Potency Cannabis on Memory

Until a few years ago, cannabis flower and edibles were the most common cannabis products on the market. The young state-legal sector enjoyed high demand and plenty of sales, but the industry blew up once concentrates hit the shelves. Concentrates have since become immensely popular, with businesses selling $797 million worth in 2020. However, while there has been an increasing number of studies on the effects of low-potency cannabis products, federal law has made it extremely hard for researchers to study high-potency cannabis.

Fortunately, researchers from Washington State University have found a way to study how high-potency cannabis affects memory without running afoul of federal law. The study, which is published in “Scientific Reports,” involved observing 80 participants over the video-conferencing platform Zoom as they consumed cannabis concentrates they had purchased for themselves in Washington state, which legalized adult use cannabis. The researchers then ran cognitive tests and found that, although the THC-loaded cannabis impaired free recall, source memory, and false memory identification, it did not impact the decision-making process.

Thanks to marijuana’s federal classification as a Schedule I controlled substance, this is just the second study on cannabis products with more than 10% THC. Running the study via Zoom, with the participants consuming their own cannabis at home, ensured the researchers did not step into a laboratory on federal property and kept the researchers from interacting with the cannabis.

The participants were split into four groups of 20; two groups used cannabis with more than 20% THC, with one of the groups using high THC cannabis that had CBD; another group vaped cannabis with CBD and 60% THC; and the last group remained sober. None of the cannabis groups were impaired in the decision-making tests, including confidence in knowledge and risk perception. In addition, memory tests found no major difference between the cannabis groups and the sober group. This includes prospective memory, which allows individuals to remember to do things later.

Additionally, the cannabis-using groups performed well on the temporal-order memory test, which tested how well they could remember the sequence of past events. However, the group that smoked high THC cannabis flower with CBD scored lower than the sober group in verbal free-recall trials, a measure of the ability to remember pictures or words they had been shown. The groups that didn’t consume cannabis flower with CBD, as well as the group that vaped concentrates with 60% THC, scored worse on a source-memory measure, which tested how well they could remember how previously learned information had been presented.

On top of that, all three cannabis groups performed poorly on a false-memory test where they were presented with a new word and, when asked if the word had been presented to them before, they tended to say it had not. Curiously, the researchers found that users of the 60% THC concentrates performed similarly to those who used lower-potency cannabis, probably because they were limiting their intake to keep their level of intoxication and impairment low.

As more researchers investigate the different ways in which various marijuana compounds affect people, the research teams are likely to benefit significantly from plant medicine dose-measuring devices such as the one made by RYAH Group Inc. (CSE: RYAH) because it will be possible to quantify how much cannabis study subjects are taking.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://cnw.fm/RYAH

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Study Finds Cannabis Terpenes Relieve Pain, Play Role in “Entourage Effect”

Cannabinoids are a range of compounds produced by plants in the cannabis family with THC, the main psychoactive component in marijuana, being the most abundant as well as the most well-known. Most of these compounds, including THC, have been found to have a variety of health benefits, with most of them producing minimal to zero psychoactive effects.

For quite a while, there has been a theory about how cannabis, when consumed as a whole, is much more effective compared to when the cannabinoids are taken separately. Dubbed the “entourage effect,” this theory states that the sum of the cannabis plant, including terpenes and flavonoids as well as cannabinoids is greater than its individual components.

A recent study from the University of Arizona Health Science has uncovered evidence to back this theory, especially regarding cannabis’ pain-relieving capabilities. The researchers found that using cannabinoids alongside terpenes had a much more impactful effect on pain, potentially providing individuals suffering from chronic pain a treatment option that would need fewer doses and result in fewer negative effects.

John Streicher, PhD, the study’s lead researcher and an associate professor of pharmacology at the College of Medicine in Tucson, Arizona, and a member of the UArizona Health Sciences Comprehensive Pain and Addiction Center, says the researchers wanted to see if they could boost THC’s “modest pain-relieving” abilities by leveraging the entourage effect. Terpenes, which are produced by many plants, not just cannabis, and are responsible for marijuana’s pungent aroma, provided interesting results.

The researchers found that cannabis terpenes mimicked cannabinoids when taken by themselves, leading to a moderate level of pain relief. Once they were used together with cannabinoids, their pain-relieving impact was boosted without any negative side effects. Since terpenes can be found in numerous plants, the researchers did not expect them to affect pain the way cannabinoids do, says Streicher, who noted that the researchers used four cannabis terpenes: linalool, beta-pinene, alpha-humulene and geraniol as well as a synthetic cannabinoid capable of stimulating the body’s cannabinoid receptors called WIN55,212-2.

Cannabinoids such as THC interact with the endocannabinoid system, binding to either CB1R or CB2R receptors. According to the researchers, the four terpenes they used attached to the CB1R receptors, with behavioral studies using mice proving that once the terpenes had interacted with the receptors, they caused three of the four classic cannabinoid effects. Those effects were reduced sensitivity to pain, reduced movement, lower body temperature and catalepsy.

Streicher hopes that the research may eventually lend a hand in the fight against the opioid crisis, especially in regard to cancer-related pain. By developing therapies that combine cannabinoids and terpenes, he would like to offer people suffering from different types of cancer-related pain a low-dosage, minimum-risk treatment option.

With the increasing availability of technologies such as the IoT dose-measuring devices being made by RYAH Group Inc. (CSE: RYAH), researchers could find it even easier to study how phtyocannabinoids, terpenes and other compounds affect human health.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://cnw.fm/RYAH

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – RYAH Group Inc. (CSE: RYAH) Announces Collaboration with University of Milan for ‘Precedent-Setting Experiment’

RYAH Group (CSE: RYAH) today announced its entry into a strategic partnership with the University of Milan, a leading education and research institution, to develop and formalize universal milliliter (“ml”) to milligram (“mg”) conversion standards in dry herb cannabis inhalation therapies for its RYAH Smart Dry Herb Inhalers. According to the update, the RYAH Smart Dry Herb Inhaler is an IoT-powered dry herb inhaler with an integrated volumetric airflow sensor that gives consumers the ability to track and control exactly how much they inhale. “Our collaboration with the University of Milan is expected to afford us an incredible opportunity to, among other things, rigorously map out how cannabis strains behave throughout a full heat-not-burn temperature spectrum at incremental volumes inhaled,” said Jordan Medley, head of product operations at RYAH. “This is a precedent-setting experiment that is expected to generate the data needed to facilitate an accurate milligram dosing experience with dry herb.”

To view the full press release, visit https://cnw.fm/dOWIn

About RYAH Group Inc.

RYAH is a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry. Its robust artificial intelligence platform aggregates and correlates HIPAA-compliant patient data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is relevant for clinics, doctors, dispensaries, pharmaceutical companies, and licensed processors (“LPs”) to monitor and manage formulation effects on patient and demographics. With a strong intellectual property portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation lifecycle. For more information about the company, visit www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://cnw.fm/RYAH

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — White House Asks for Comments on How Underserved Communities Face Barriers Due to Drug Policies

Despite starting with relatively noble intentions, the drug war is considered an unmitigated failure by many. Not only did it fail to sufficiently curb drug use or suppress the criminal enterprises behind the drug trade, but it also ensured that certain communities were intensely policed and harshly sentenced for decades. Now that America’s state-legal cannabis sector is steadily growing, some policies from the drug war era that have endured may be creating “systemic barriers” for these communities.

As such, the White House, via its drug policy arm, has opened a 30-day comment period in a bid to see whether existing drug policies have barred underserved communities from accessing opportunities and whether policymakers can create programs to help ensure equity. Additionally, the Office of National Drug Control Policy (“ONDCP”) is also seeking counsel from drug users to see how it could better involve them when creating policies that ultimately impact them. The ONDCP published the notice in the Federal Register, and the notice is bound to attract plenty of attention from drug reform advocates.

The ONDCP was founded in the 1980s, with help from President Joe Biden who was a senator at the time. Over the years, the agency has been quite resistant to drug reform such as cannabis legislation, and advocates have often questioned whether the office is even necessary. The notice for feedback on how drug policies may affect equity wasn’t issued independently by the agency;  rather, it is part of a governmentwide executive order signed by President Biden in January.

Specifically, the executive order requires agencies to determine whether their programs and policies provide systemic barriers for underserved communities and people of color and bars these individuals from accessing opportunities and benefits, the ONDCP says. Via a series of prompts, the agency states that it is looking for more perspectives from people of wide-ranging backgrounds, especially those who were disproportionately impacted by America’s drug policies to help guide its efforts in the future. The White House’s drug policy arm is currently in charge of the High-Intensity Drug Trafficking Areas Program, which enables the war on drugs, and sufficient feedback could help the office tailor its policies and reduce the intense policing and harsh sentencing that communities of color face.

The agency is also interested in receiving feedback from “people who use drugs,” especially those who are usually left out of household surveys, to aid in the process of developing national drug control policy. Individuals who would like to provide feedback to the ONDCP can do so at OGC@ondcp.eop.gov until Aug. 6, 2021.

Hopefully the comments sent will result in the formulation of policies that make it easier for medical marijuana users to access devices such as the RYAH Smart Inhaler made by RYAH Group Inc. (CSE: RYAH), which helps cannabis users to determine the dosage of medical marijuana they consume.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://cnw.fm/RYAH

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Fibromyalgia Patients Ditching Opioids for CBD to Manage Pain

Fibromyalgia is a disorder that presents as musculoskeletal pain accompanied by mood, memory, sleep and fatigue issues. This disorder has no cure, and while there are drugs that can help manage its symptoms, most don’t do the job perfectly. However, a new study conducted by researchers from the School of Medicine at the University of Michigan has found that patients with fibromyalgia may benefit from the use of products that contain CBD to manage pain.

CBD, or cannabidiol, is a cannabinoid that is extracted from the marijuana plant that doesn’t induce the intoxicating effects of THC. This cannabinoid has been marketed for different uses, ranging from pain relief to mood stabilization. THC, or delta-9-tetrahydrocannabinol, is another cannabinoid that is also extracted from the marijuana plant. It causes individuals to feel high.

The legalization of recreational and medical cannabis in different states across the United States and the removal of CBD derived from hemp from its Schedule 1 classification have boosted the marijuana industry’s growth tremendously.

Prior studies have demonstrated that some individuals substitute medical marijuana, which has high THC concentration, for pain medications such as opioids, with many reporting that the former induces fewer side effects and offers better pain relief. However, studies on the use of CBD for the same indications is still limited at best.

This is why researchers from the Chronic Pain and Fatigue Research Center conducted their research, with Kevin Boehnke, a member of the research team, noting that CBD was less harmful in comparison with THC and presented a beneficial harm reduction strategy. The researchers conducted a survey with more than 800 individuals who suffer from fibromyalgia and claimed to use CBD to manage chronic pain.

In the study, the research investigators explained that the disease wasn’t easy to treat and involved different medications that provide modest benefits and many side effects, noting that alternative therapies such as massages and acupuncture weren’t covered by insurance, which made those options less accessible to most individuals. The researchers discovered that more than 70% of the individuals who used CBD had substituted it for other pain medications, including opioids. Of this number, the majority reported that they had either stopped taking or reduced their use of opioids due to the use of CBD.

The researchers note that for most of the patients, the use of CBD was taking place without the guidance of a physician, adding that despite the lack of evidence, individuals who were using the cannabinoid as a substitute for other pain medications had found it to be more efficacious and less harmful.

As devices like the RYAH Smart Inhaler made by RYAH Group Inc. (CSE: RYAH) become increasingly available, patients who use cannabis for pain and other symptoms will find it easier to monitor and record the doses of marijuana they need for symptom relief.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://cnw.fm/RYAH

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Researchers Find Marijuana May Be Used to Alleviate Pain Caused by Sickle Cell

clinical trial that was conducted by researchers from the University of California-Irvine in collaboration with UC San Francisco has found that marijuana has the potential to be used as a treatment for chronic pain in patients suffering from sickle cell disease. The trials discoveries were reported in JAMA Network Open.

Prof. Kalpna Gupta, who is a member of the Irvine institution’s Center for the Study of Cannabis as well as being an Irvine researcher, states that the trial led them to the discovery that vaporized marijuana is generally safe, suggesting that patients suffering from sickle cell anemia may alleviate their pain using marijuana, which may also be used to address the opioid crisis.

Gupta, who has specialized in medicine, adds that larger studies that have more participants may present researchers with a better view of how marijuana can help individuals suffering from chronic pain.

Opioids are the principal drugs prescribed to manage acute and chronic pain caused by sickle cell disease. However, the increase in deaths linked to opioids has prompted clinicians to prescribe them less, which leaves patients with chronic pain with fewer options.

The placebo-controlled, double-blind randomized trial conducted by the pair of institutions was the first to make use of gold-standard techniques to evaluate the potential of marijuana in pain relief for people suffering from sickle cell disease. The marijuana utilized in the trial contained equal parts of CBD and THC and was acquired from the National Institute on Drug Abuse, which is under the NIH.

Gupta stated that facing so much pain caused many individuals to turn to marijuana, adding that this was the main reason why people sought the herb from dispensaries. She explained that while researchers weren’t sure whether all forms of marijuana products would have the same effect on chronic pain, they were certain that vaporized marijuana was safer in comparison with other forms, as small amounts reach the body’s circulation.

For the trial, 23 patients who each suffer from pain related to sickle-cell disease were recruited. During the two 5-day inpatient sessions, which were separated by a 4-week period, each patient inhaled a vaporized placebo or vaporized marijuana.

The researchers then evaluated the pain level of each participant throughout the treatment period, which led to the discovery that marijuana’s efficaciousness grew over time. The participants also revealed that their pain didn’t affect their moods or activities such as sleeping and walking.

In addition to this, the researchers note that the level of pain was lower in patients who had inhaled vaporized marijuana in comparison with those who had received the placebo.

With companies such as RYAH Group Inc. (CSE: RYAH) making smart inhalers that allow patients to be sure about the amount of medical marijuana they are inhaling for pain, it may just be a matter of time before cannabis medicine is as widely accepted as pharmaceuticals.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://cnw.fm/RYAH

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – RYAH Group Inc. (CSE: RYAH) Announces Shipment of Proprietary Dry Herb Inhalers for Use in Pilot Program

RYAH Group (CSE: RYAH), a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry, has  completed an initial shipment of its proprietary RYAH Smart Dry Herb Inhalers. The shipment was sent to Medicann in Jersey, the largest of the Channel Islands, located between England and France. A premier cannabis-specialized clinic, Medicann plans to use the inhalers for use in a pilot program designed to collect patient feedback regarding consumption of cannabis strains that are available on the island. According to the announcement, the parties will also be working on defining an exclusive, definitive supply and distribution agreement that would name Medicann as the sole supplier and distributor of the RYAH Smart Dry Herb Inhalers in the region. “We are excited to be initiating our pilot program with Medicann in Jersey, which represents a unique, ‘ring-fenced’ environment for establishing potentially numerous studies on the efficacy of treatments using plant-based therapies,” said RYAH Group CEO Gregory Wagner in the press release. “RYAH is pleased to contribute RYAH’s IoT devices and data platform and work with Medicann toward perfecting prescribing practices and dosing regimens.”

To view the full press release, visit https://nnw.fm/YIBSg

About RYAH Group Inc.

RYAH Group is a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry. Its robust artificial intelligence platform aggregates and correlates HIPAA-compliant patient data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is relevant for clinics, doctors, dispensaries and pharmaceutical companies and licensed processors (“LPs”) to monitor and manage formulation effects on patients and demographics. With a strong IP (“IP”) portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation life cycle. For more information about the company, please visit www.RyahGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://cnw.fm/RYAH

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Massachusetts Regulators Extend Cannabis Telehealth, Curbside Pickup

At the onset of the coronavirus pandemic last year, the Massachusetts Cannabis Control Commission permitted medical cannabis patients to access telehealth appointments and have their prescriptions delivered for curbside pickup in an attempt to increase safety. Consumers were allowed to place their orders either online or via phone; they could then pick up those orders curbside at the stores.

Now, the agency notes, the measures will be allowed to continue for an extended period, despite the State of Emergency declared by Gov. Charlie Baker of Massachusetts coming to an end. The State of Emergency was initially declared in the state on March 10, 2020.

While issuing final administrative orders at the start of this week, the Cannabis Control Commission’s executive director, Shawn Collins, stated that virtual community outreach meetings, telehealth consults and curbside operations would be allowed to continue until Sept. 1, 2021.  However, this date could change if the administrative orders are amended or the commission revokes the order.

For medical patients, clinical visits for purposed such as renewal and consultation can carry on through telehealth appointments. Additionally, individuals who have yet to register but would like to do so are encouraged to do so through telehealth up until September 1. The order notes that after the aforementioned date, clinical visits can occur either by telehealth or in person. As per medical-use regulations, however, any first-time patient will have to visit a clinic in person in order to be issued with an initial certificate of registration.

In addition to this, marijuana dispensaries can continue to carry out sales for curbside pickup by electronic means and by phone. This, the order asserts, will help keep both customers and patients safe.

The commission also stated that virtual meetings could be conducted by any individual who would like to host a community outreach meeting, as it would be safe and also allow those who couldn’t attend physical gatherings to also take part in them.

In other news, Cloud Creamery is planning on launching marijuana-infused ice cream in the state, as summer sets in. Residents in the state already have access to edible chocolate bars and gummies. Now, David Yusefzadeh of Cloud Creamery wants to heighten the edibles experience by utilizing local products, which will not only attract new consumers but also boost the industry’s growth.

At the start of the month, the state’s Cannabis Control Commission issued a notice to Cloud Creamery, giving the company the go ahead to begin manufacturing operations. The product will be available at Caroline’s Cannabis in UxbridgeWestern Front in Chelsea and Bud’s Goods and Provisions in Worcester.

Yusefzadeh also plans to bring traffic to minority and women-owned dispensaries, when the product begins to be offered at dispensaries.

The extension of telehealth services and curbside pickups is a good move as it recognizes how important medical cannabis products are to the people who need them. These benefits can further be exploited by making use of the range of products, such as the remote IoT dose-measuring device,made by RYAH Group Inc. (CSE: RYAH) to help patients take precise doses of their plant medicine.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://cnw.fm/RYAH

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — NFL Funds Cannabis Research Despite Continued Prohibition Hindering Research

The NFL-NFLPA Committee, which was formed by the players’ union in the National Football League and the NFL, recently revealed its plans to award grants to researchers to facilitate research on the therapeutic potential of CBD, cannabis and other opioid alternatives for pain management.

During a press conference held last week, a representative from the Joint Pain Management Committee stated that there were numerous innovative ideas in the psychedelics space, adding that important research needed to be financed.

Dr. Kevin Hill, co-chair of the committee, stated that the federal policy unfavorably affected the level of research permitted, given the ongoing prohibition of marijuana, which is still categorized as a Schedule I drug. Hill also noted that lack of financing in this field of research also affected advancements in research. He explained that many companies and states that were profiting significantly through the sale of marijuana as well as other cannabinoids weren’t contributing to science.

This funding opportunity aims at requesting proposals from researchers who have the ability to conduct studies that can supplement the committee’s knowledge on athletic performance and pain management in football players. In particular, the league would like proposals on the following areas of inquiry:

  • The effects of cannabinoids or marijuana on athletic performance in football players, e.g., in reaction time, cardiorespiratory or psychomotor function
  • The effects of nonpharmacologic treatments on pain in football players, be it everyday pain management or postsurgical pain management
  • The effects of cannabinoids on pain in football players

notice released by the NFL states that the deadline for applications to be submitted prior to proposals is July 31, 2021.

In 2020, the joint panel held CBD informational forums, which led to the determination that the marijuana compound, which is nonintoxicating, shows potential in the treatment of various forms of pain. However, the committee felt there was not enough information and research existed on the benefits of opioid alternatives for both chronic and acute pain.

The NFL policy also highlights that players in the league won’t face suspension from games based on positive tests for any substance, including cannabis. This policy, which was recently revised, reflects a considerable shift in the NFL’s approach to the use of drugs by players, with the agreement highlighting the need to center on treatment and evaluation rather than penalties.

Players who self-refer themselves, display behaviors that indicate misuse of drugs or test positive for drug use are now required to enroll in an intervention program, where they can be evaluated and receive a treatment plan.

As more becomes known about the therapeutic potential of marijuana and its compounds, the dose-measuring devices made by companies such as RYAH Group Inc. (CSE: RYAH) are likely to see an upsurge in demand.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://cnw.fm/RYAH

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Study Finds Medical Cannabis Containing THC Can Work Better Than Cannabidiol

The past decade has seen medical cannabis become exceedingly popular as more than 30 states have passed legislation allowing qualifying patients to use marijuana for medical purposes. Consequently, there has been increased, although still limited, research into marijuana’s medical potential, and one theory has almost become a fact in many people’s minds. THC (delta-9 tetrahydrocannabinol), the main psychoactive agent in cannabis, has been unofficially dubbed the fun cannabinoid that has barely any medicinal properties and gets users high while CBD (cannabidiol) is the medical powerhouse responsible for marijuana’s purported medical abilities.

Most of state-legal medical cannabis programs only allow cannabis with very limited THC levels, and a majority of companies in the medical marijuana space have leaned into the “THC is for fun, but CBD is medicinal” theory. However, a recent study found that this theory may be wrong, with plenty of cannabis users deriving immediate and effective relief from nausea after consuming cannabis strains with more THC and less CBD. Conducted by researchers at the University of New Mexico, the study has been described as the largest study of its kind.

To arrive at this conclusion, the researchers tracked cannabis users’ habits, symptoms, the cannabis products they used and the consequent relief (or lack of) they felt after consuming cannabis via the Releaf app. Not only did the researchers deduce that THC-dominant cannabis offered relief against nausea in as little as five minutes but that smoking cannabis flower offered the individuals faster, more substantial relief compared to using edibles or vaporizers. Cannabis products with more THC were generally more effective than CBD-dominant cannabis products, with research published in the Journal of Clinical Gastroenterology” in April reporting that cannabis users who consumed products high in CBD achieved less relief on average.

The researchers analyzed 886 cannabis users looking to obtain nausea relief from June 6, 2016, to July 8, 2019, through an estimated 2,220 self-administration sessions. The users reported which specific products they were using, the symptoms they were trying to eliminate and how these symptoms reacted to cannabis, all in real time. Jacob Vigil, the study’s co-author and associate professor of psychology at the University of New Mexico, says that this discovery was quite surprising to the researchers.

However, the study co-author and the lead author of the study Dr. Sarah Stith, who is also an assistant professor of economics at the University of New Mexico, reported that this study doesn’t give THC the all clear. The substance still presents significant long-term effects on high-risk individuals such as pregnant women and children, and nausea is only one area in which THC may shine brighter than CBD. While there are other symptoms that cannabidiol may relieve more effectively than THC, this study provides evidence against the prevalent theory that THC will just get you high but CBD is packed with medicinal properties.

As this scientific proof mounts, companies such as RYAH Group Inc. (CSE: RYAH), which makes devices that can help patients measure their medical cannabis dosage more accurately, will see a heightened demand for their products.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://cnw.fm/RYAH

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.